Skip to main content
MedWatcherBeta

Loading research and source information…

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy for Multiple sclerosis: evidence and status · MedWatcher